CIBC Private Wealth Group’s Praxis Precision Medicines PRAX Stock Holding History

CIBC Private Wealth Group’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.01K	Buy	+17	New	+$3.17K	﹤0.01%	2623

Other funds holding PRAX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

CIBC Private Wealth Group's PRAX Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Praxis Precision Medicines (PRAX) in Q4 2025: 17 shares worth $5.01K. The stake represents ﹤0.01% of the portfolio and ranks #2623 among its holdings.

250 funds tracked by Wall St. Rank hold PRAX as of Q4 2025.

CIBC Private Wealth Group held 17 shares of Praxis Precision Medicines worth $5.01K as of Q4 2025.
Praxis Precision Medicines was a new CIBC Private Wealth Group position in Q4 2025.
Praxis Precision Medicines made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2623 holding.
250 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.